Jacksonville, FL, September 02, 2017 --(PR.com
)-- Robert P. Giugliano, M.D., Senior Investigator with the TIMI Study Group, will be the keynote speaker at the American Society for Preventive Cardiology (ASPC) 2017 Congress on CVD Prevention in Fort Lauderdale, Fla. on Friday, Sept. 15.
The three-day event, running from Sept. 15-17, will take place at the oceanfront Westin Fort Lauderdale Beach Resort. Room reservations and meeting registration can be accessed at aspconline.org/congress.
A respected cardiologist and associate professor of medicine at Harvard Medical School, Giugliano’s keynote presentation will address the present and future of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel cholesterol lowering agent and major breakthrough in cardiovascular therapeutics. Giugliano will review the data from FOURIER and other key trials that are being translated into new therapeutic strategies for clinical practice.
On Saturday, Sept. 16, Martha Gulati, M.D., M.S., F.A.S.P.C., professor of medicine and chief of the division of cardiology at the University of Arizona-Phoenix, will present the Nanette K. Wenger Distinguished Lecture. Gulati is an internationally recognized expert on women with heart disease. She will discuss the physician’s approach in treating heart disease in women and why specialized care is needed for women’s hearts and vessels.
The closing presentation on Sunday, Sept. 17, features a debate on usefulness of advanced lipoprotein testing. Allan D. Sniderman, M.D., professor of cardiology at McGill University, will argue the pro side highlighting advanced lipoprotein testing as a key tool for preventive cardiologists. Jennifer G. Robinson, M.D., M.P.H., professor and director of the preventive intervention center at the University of Iowa, will present a different viewpoint, arguing the testing is more hype than help.
The Congress will also feature a town hall forum titled, “PCSK9 Inhibitor Access Barriers: Issues and Recommendations: Improving the Access Process for Patients, Clinicians, and Payers.” The event will discuss a publication that summarizes barriers to access PCSK9 inhibitors and provide tools and resources to overcome the hurdles in accessibility. The town hall, set for Friday, Sept. 16, will be hosted by authors of the publication and thought leaders in preventive cardiology.
In addition to watching world-renowned speakers, attendees will have the chance to connect with the faculty and other prominent preventive cardiology leaders. During the conference, practitioners will gain real-world perspective on how to translate current cardiovascular disease prevention research into effective treatment strategies for clinical practice.
For those not able to attend, ASPC is also offering the event via live stream and on-demand. For more information, visit aspconline.org/congress-live-streaming.
About the American Society for Preventive Cardiology
The American Society for Preventive Cardiology is a national organization of healthcare providers and researchers dedicated to the prevention of atherosclerotic cardiovascular disease. The mission of the ASPC is to promote the prevention of atherosclerotic cardiovascular disease, advocate for the prevention of cardiovascular health, and disseminate high-quality, evidence-based information through education of clinicians.